In8Bio (INAB) Capital Expenditures (2020 - 2026)

In8Bio (INAB) posted Capital Expenditures of -$17000.0 for Q1 2026, up 65.31% sequentially from -$49000.0 in Q4 2024.

In8Bio (INAB) Capital Expenditures (2020 - 2026) Analysis & Trends

In8Bio has reported Capital Expenditures for 5 years, with the latest figure at -$17000.0 in Q1 2026.

Quarterly Capital Expenditures changed N/A year-over-year to -$17000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$17000.0 (up 62.22% YoY) and the FY2024 annual result came in at $20000.0, down 95.06% from the prior year.
Capital Expenditures rose to -$17000.0 in Q1 2026 per INAB's latest filing, from -$49000.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $3.6 million in Q4 2022 and troughed at -$349000.0 in Q2 2023.
A 4-year average of $341416.7 and a median of $6000.0 in 2022 frame the typical range for Capital Expenditures.
The widest YoY moves for Capital Expenditures: up 4537.5% in 2023, down 536.25% in 2023.
Over 4 years, Capital Expenditures stood at $3.6 million in 2022, then slumped by 88.88% to $405000.0 in 2023, then plunged by 112.1% to -$49000.0 in 2024, then surged by 65.31% to -$17000.0 in 2026.
According to Business Quant data, Capital Expenditures over the past three periods registered -$17000.0, -$49000.0, and $4000.0 for Q1 2026, Q4 2024, and Q3 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	140.23 Bn	132.38 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	86.97 Bn	78.97 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	65.29 Bn	60.11 Bn	1.37 Bn	-
4	Moderna	59.88 Bn	54.74 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	42.20 Bn	37.11 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.62 Bn	28.31 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.69 Bn	10.30 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.16 Bn	26.33 Bn	-	251.02 Mn
10	In8Bio	23.75 Mn	23.75 Mn	-	259,000.00

Download Data